76. Hagan P, Blumenthal UJ, Dunn D, et al. Human IgE, IgG4 and resistance to infection with *Schistosoma haematobium*. *Nature* 1991; 349: 243-5
77. Dunne DW, Butterworth AE, Fulford AJC, et al. Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to infection. *Eur J Immunol* 1992; 22: 1483-94
78. Sutton BJ, Gould HJ. The human IgE network. *Nature* 1993; 366: 421-8
79. Heyman B, Tianmin L, Gustavsson S. *In vivo* enhancement of the specific antibody response via the low-affinity receptor for IgE. *Eur J Immunol* 1993; 23: 1739-42
80. Kühn R, Rajevsky K, Müller W. Generation and analysis of IL-4 deficient mice. *Science* 1991; 254: 707-10
81. Haba S, Nisonoff A. Inhibition of IgE synthesis by anti-IgE: role of long-term inhibition of IgE synthesis by neonatally administered soluble IgE. *Proc Natl Acad Sci USA* 1990; 87: 3363-7
82. Hellman L. Profound reduction in allergen sensitivity following treatment with a novel allergy vaccine. *Eur J Immunol* 1994; 24: 415-20
83. Levy DA, Chen J. Healthy IgE-deficient person. *N Engl J Med* 1970; 283: 541
84. Helm B, Marsh P, Vercelli D, et al. The mast cell binding site on human immunoglobulin E. *Nature* 1988; 331: 180-3
85. Helm B, Kebo D, Vercelli D, et al. Blocking of passive sensitization of human mast cells and basophil granulocytes with IgE antibodies by a recombinant human ϵ -chain fragment of 76 amino acids. *Proc Natl Acad Sci USA* 1989; 86: 9465-9
86. Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. *J Immunol* 1993; 151: 2623-32
87. Chang TW, Davis FM, Sun N-C, et al. Monoclonal antibodies specific for human IgE-producing B-cells: a potential therapeutic for IgE-mediated allergic diseases. *Bio/Technology* 1990; 8: 122-6
88. Davis FM, Gossett LA, Pinkston KL, et al. Can anti-IgE be used to treat allergy? *Springer Semin Immunopathol* 1993; 15: 51-73
89. Froehlich J, Schoenhoff M, Jardieu P, et al. Multiple doses of a recombinant humanized monoclonal anti IgE antibody are safely tolerated and decreased free serum IgE to undetectable levels [abstract no. 863]. *J Allergy Clin Immunol* 1995; 95: 356
90. Bates D, Ruppel J, Fei BAD, et al. Pharmacokinetics/dynamics following administration of recombinant humanized monoclonal anti IgE antibody in *Cynomolgus* monkey [abstract no. 864]. *J Allergy Clin Immunol* 1995; 95: 365
91. Haba S, Nisonoff A. Induction of high titers of anti-IgE by immunization of inbred mice with syngeneic IgE. *Proc Natl Acad Sci USA* 1987; 84: 5009-13
92. Haba S, Nisonoff A. Immunological responsiveness of neonatal A/J mice to isotypic determinants of syngeneic IgE. *J Exp Med* 1988; 168: 713-24
93. Haba S, Nisonoff A. Role of antibody and T cells in the long-term inhibition of IgE synthesis. *Proc Natl Acad Sci USA* 1994; 91: 604-8
94. Haba S, Nisonoff A. Effect of syngeneic anti-IgE antibodies on the development of IgE memory and on the secondary IgE response. *J Immunol* 1994; 152: 51-7
95. Marshall JS, Bell EB. Induction of an auto-anti-IgE response in rats. I. Effects on serum IgE concentrations. *Eur J Immunol* 1985; 15: 272-7
96. Marshall JS, Prout SJ, Jaffery G, et al. Induction of an auto-anti-IgE response in rats. II. Effects on mast cell populations. *Eur J Immunol* 1987; 17: 445-51
97. Marshall JS, Bell EB. Induction of an auto-anti-IgE response in rats. III. Inhibition of a specific IgE response. *Immunology* 1989; 66: 428-33

Correspondence and reprints: Dr Lars Hellman, Department of Medical Immunology and Microbiology, Biomedical Centre, Box 582, University of Uppsala, S-751 23 Uppsala, Sweden.

Erratum

Vol. 5, No. 1, page 50, table V and page 53, section 3.4.4: The FDA risk category for methotrexate should be X.

[Ramsey-Goldman R, Schilling E. Optimum use of disease-modifying and immunosuppressive antirheumatic agents during pregnancy and lactation. *Clin Immunother* 1996 Jan; 5 (1): 40-58]